Acetate is the most abundant SCFA in the colon and makes up more than half of the total SCFA detected in feces.
Acetate is the most abundant SCFA in the colon and makes up more than half of the total SCFA detected in feces.
Acetate is another SCFA produced by gut bacteria through the fermentation of prebiotic fibers like inulin and GOS or unabsorbed peptides and fats. Gut-derived acetate production is tightly regulated within the microbiome and determined by the presence of prebiotic fiber and the balance between saccharolytic and proteolytic fermentation. Acetate is used for cholesterol synthesis and lipogenesis but can also be utilized by muscle tissue. Additionally, some gut bacteria like Roseburia spp and Faecalibacterium prausnitzii can convert acetate into butyrate. Excessive acetate production combined with insufficient butyrate production can lead to fat gain, particularly around the liver.
The biomarker Acetoacetate, measured in serum or plasma (S/P) is a key component in the evaluation of ketone body levels within the human body. Acetoacetate is one of the three primary ketone bodies, alongside beta-hydroxybutyrate and acetone, produced during the process of ketogenesis, which occurs primarily in the mitochondria of liver cells. This metabolic process is triggered under conditions where glucose availability is insufficient to meet the body's energy demands, such as during prolonged fasting, carbohydrate-restricted diets, or uncontrolled diabetes mellitus. The measurement of acetoacetate is critical in diagnosing and monitoring conditions associated with altered metabolic states, such as diabetic ketoacidosis (DKA), starvation ketosis, and alcoholic ketoacidosis. In DKA, for example, the inability of cells to utilize glucose due to insufficient insulin leads to increased fatty acid oxidation and subsequent ketogenesis, resulting in elevated levels of acetoacetate and other ketone bodies. These compounds can accumulate to toxic levels, leading to metabolic acidosis, a potentially life-threatening condition characterized by decreased blood pH and altered electrolyte balance. Elevated acetoacetate levels may necessitate interventions such as insulin therapy in the case of diabetic patients, nutritional support for those with starvation ketosis, or specific treatments addressing the underlying causes of increased ketogenesis. This marker, by reflecting the balance between carbohydrate availability and the body's energy requirements, provides critical insights into the patient's metabolic state, facilitating timely and appropriate medical response.
A ketone body
A ketone body
A ketone body
A ketone body
A ketone body
A ketone body
Volatile substances in the blood include ethanol, methanol, isopropanol, and acetone. Acetone is generally elevated in metabolic conditions such as diabetic ketoacidosis. Methanol and isopropanol are highly toxic and result from exogenous ingestion. The presence of acetone may indicate exposure to acetone; it is also a metabolite of isopropanol and may be detected during ketoacidosis.
Mitochondrial energy metabolite
This is the primary diagnostic test for myasthenia gravis.
autoantibodies produced by the immune system
What Is the AChR Binding Antibodies Test? The AChR Binding Antibodies, Serum test measures the presence of autoantibodies against acetylcholine receptors (AChRs) in the blood. These antibodies interfere with the normal communication between nerves and muscles and are commonly associated with myasthenia gravis (MG) — a chronic autoimmune disorder that causes muscle weakness and fatigue. This test specifically looks for binding antibodies, the most common type found in people with MG. Why Is This Test Important? Acetylcholine is a chemical messenger that tells your muscles to contract. In myasthenia gravis, the immune system produces antibodies that block or destroy the acetylcholine receptors on muscle cells, preventing proper muscle activation. Detecting AChR binding antibodies in the blood helps confirm the diagnosis and guides treatment decisions. Who Should Get This Test? Your doctor may recommend this test if you experience symptoms such as: Drooping eyelids (ptosis) Double vision (diplopia) Muscle weakness that worsens with activity Difficulty swallowing, speaking, or breathing Fatigue in the arms, legs, or neck It may also be used to monitor disease progression or response to therapy in people already diagnosed with MG. What Do the Results Mean? Positive Result: A positive test means AChR binding antibodies are present, supporting a diagnosis of autoimmune myasthenia gravis. Most individuals with generalized MG will test positive. This finding helps confirm that symptoms are due to an autoimmune attack on acetylcholine receptors. Negative Result: A negative result means that AChR binding antibodies were not detected, but this does not fully rule out myasthenia gravis. Some people with MG may have other types of antibodies, such as MuSK or LRP4 antibodies, or may test negative altogether (seronegative MG). Additional testing may be necessary. How Is the Test Performed? This test requires a blood sample taken from a vein in your arm. No fasting or special preparation is needed beforehand. Summary The AChR Binding Antibodies, Serum test is a key diagnostic tool for myasthenia gravis, helping identify the autoimmune attack on the neuromuscular system. A positive result can confirm the diagnosis and allow for earlier, more targeted treatment to manage symptoms and improve quality of life.
What Are AChR Blocking Antibodies? AChR Blocking Antibodies are a type of autoantibody that interfere with how acetylcholine receptors (AChRs) work at the neuromuscular junction—the place where nerves signal muscles to contract. These antibodies block the receptors, preventing proper nerve-to-muscle communication. This test measures the blocking antibodies specifically, which are one subset of acetylcholine receptor antibodies commonly involved in myasthenia gravis (MG)—a chronic autoimmune neuromuscular disorder that causes weakness in voluntary muscles. Why Is This Test Important? AChR Blocking Antibodies are found in a significant number of people with myasthenia gravis, especially those with generalized symptoms affecting the face, limbs, and respiratory muscles. This test helps confirm a diagnosis and can be especially helpful when other types of AChR antibodies (like binding or modulating) are also being evaluated. Symptoms That May Prompt This Test: Drooping eyelids (ptosis) Double vision (diplopia) Difficulty swallowing or speaking Muscle weakness that worsens with activity Breathing difficulties in severe cases What Do the Results Mean? Positive Result: A positive result for AChR blocking antibodies supports a diagnosis of myasthenia gravis, indicating that the immune system is blocking the communication between nerves and muscles. This helps guide treatment decisions such as immunosuppressive therapy or acetylcholinesterase inhibitors. Negative Result: A negative test means these specific antibodies were not found in your blood, but it does not rule out myasthenia gravis. Some individuals may have different types of AChR antibodies (binding or modulating), MuSK antibodies, or may be seronegative (no detectable antibodies despite having MG symptoms). How Is the Test Performed? The test is done using a blood sample, typically drawn from a vein in your arm. No special preparation is required. In Summary The AChR Blocking Antibodies, Serum test helps detect one of the key autoimmune markers of myasthenia gravis. If you're experiencing muscle weakness or other unexplained neuromuscular symptoms, this test—along with other antibody tests—can play a vital role in diagnosing and managing the condition effectively.
What Is the AChR-Modulating Antibody? The AChR-Modulating Antibody test detects autoantibodies that disrupt communication between nerves and muscles by targeting and altering acetylcholine receptors (AChRs) on muscle cells. These antibodies are commonly found in people with myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder. The term “modulating” refers to the antibody’s ability to change the number or function of acetylcholine receptors, making it harder for muscles to respond to nerve signals, which leads to muscle weakness and fatigue. Why Is This Test Important? This test is part of a broader diagnostic panel for myasthenia gravis. While other AChR antibody tests (such as binding or blocking antibodies) show whether antibodies are present, the modulating antibody test specifically shows whether those antibodies are actively interfering with receptor function on the surface of muscle cells. Identifying this type of antibody helps confirm a diagnosis of MG and guides treatment decisions. Symptoms That May Prompt Testing Drooping eyelids (ptosis) Double vision (diplopia) Trouble speaking, chewing, or swallowing Muscle weakness in the arms, legs, or neck Symptoms that get worse with activity and improve with rest What Do the Results Mean? Positive result: A positive AChR-modulating antibody test suggests that your immune system is producing antibodies that interfere with acetylcholine receptors, supporting a diagnosis of myasthenia gravis. This can help your doctor decide on immunosuppressive treatment or medications that improve nerve-muscle communication. Negative result: A negative result means these specific antibodies were not found, but it does not fully rule out myasthenia gravis. Other types of AChR antibodies (binding or blocking), or antibodies like MuSK, might still be present. Further testing or electromyography (EMG) may be needed if symptoms persist. How Is the Test Performed? The AChR-modulating antibody test is done using a blood sample. No special preparation is needed. Summary The AChR-Modulating Antibody test helps detect an autoimmune attack on muscle receptors in people with suspected myasthenia gravis. A positive result supports the diagnosis and helps guide effective treatment to manage muscle weakness and improve quality of life.
Increased risk of multiple sclerosis